CN121532183A - Kras g12s和g12c抑制剂 - Google Patents

Kras g12s和g12c抑制剂

Info

Publication number
CN121532183A
CN121532183A CN202480046678.5A CN202480046678A CN121532183A CN 121532183 A CN121532183 A CN 121532183A CN 202480046678 A CN202480046678 A CN 202480046678A CN 121532183 A CN121532183 A CN 121532183A
Authority
CN
China
Prior art keywords
fluoro
pyrido
compound
methoxy
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480046678.5A
Other languages
English (en)
Chinese (zh)
Inventor
王晓仑
M·A·马克思
J·D·劳森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milady Treatment Co
Original Assignee
Milady Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milady Treatment Co filed Critical Milady Treatment Co
Publication of CN121532183A publication Critical patent/CN121532183A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202480046678.5A 2023-05-15 2024-05-15 Kras g12s和g12c抑制剂 Pending CN121532183A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363466476P 2023-05-15 2023-05-15
US63/466,476 2023-05-15
US202463626329P 2024-01-29 2024-01-29
US63/626,329 2024-01-29
PCT/US2024/029427 WO2024238633A2 (fr) 2023-05-15 2024-05-15 Inhibiteurs de kras g12s et g12c

Publications (1)

Publication Number Publication Date
CN121532183A true CN121532183A (zh) 2026-02-13

Family

ID=93520267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480046678.5A Pending CN121532183A (zh) 2023-05-15 2024-05-15 Kras g12s和g12c抑制剂

Country Status (4)

Country Link
EP (1) EP4712961A2 (fr)
KR (1) KR20260010430A (fr)
CN (1) CN121532183A (fr)
WO (1) WO2024238633A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
CN121605110A (zh) 2023-06-06 2026-03-03 金橘生物科技公司 取代杂环化合物及其用途
WO2025101776A1 (fr) * 2023-11-08 2025-05-15 Kumquat Biosciences Inc. Hétérocycles et leurs utilisations
WO2025167948A1 (fr) * 2024-02-06 2025-08-14 上海齐鲁制药研究中心有限公司 Inhibiteur de kras macrocyclique à base de pyrimidine
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026035947A1 (fr) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction par liaison covalente ciblant kras comprenant une charge utile de topo-isomérase
WO2026035945A1 (fr) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026064527A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline
WO2026064520A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
EP4291199A4 (fr) * 2021-02-09 2025-06-18 Kumquat Biosciences Inc. Composés hétérocycliques et leurs utilisations
US20240166669A1 (en) * 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
WO2022256459A1 (fr) * 2021-06-01 2022-12-08 Quanta Therapeutics, Inc. Modulateurs de kras et leurs utilisations
JP2025527530A (ja) * 2022-08-16 2025-08-22 ブリストル-マイヤーズ スクイブ カンパニー Kras阻害剤

Also Published As

Publication number Publication date
WO2024238633A3 (fr) 2025-05-15
KR20260010430A (ko) 2026-01-20
EP4712961A2 (fr) 2026-03-25
WO2024238633A2 (fr) 2024-11-21

Similar Documents

Publication Publication Date Title
CN121532183A (zh) Kras g12s和g12c抑制剂
KR102861303B1 (ko) Kras g12c 억제제
KR102862474B1 (ko) Parp7 억제제로서의 피리다지논
CN112437772B (zh) Bcl-2抑制剂
AU2022232523A1 (en) Kras g12d inhibitors
AU2018243691B2 (en) Heterocyclic compound
JP2025506408A (ja) キナゾリンpan-KRas阻害剤
AU2021401232A9 (en) Azaquinazoline pan-kras inhibitors
CN119677748A (zh) 氢吡啶并嘧啶泛KRas抑制剂
AU2017259436A1 (en) Piperidines as menin inhibitors
TW202409030A (zh) 五元並六元含氮化物、其中間體、製備方法和應用
EP3681885B1 (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
CN116057061B (zh) Usp7抑制剂
CN118660880A (zh) 喹唑啉泛KRas抑制剂
CN121464131A (zh) Mllt1和mllt3抑制剂化合物
WO2025255298A1 (fr) Inhibiteurs de pkc-thêta, compositions et procédés d'utilisation
WO2024220399A1 (fr) Pyrazolotriazinecarbonitriles utiles en tant qu'inhibiteurs de kinase
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication